Navigation Links
Rich or poor in gut bacteria brings new vision for obesity treatment
Date:8/29/2013

Shenzhen, China -- The MetaHIT consortium, comprised of Institute National de la Recherche Agronomique (INRA), University of Copenhagen, BGI, and other institutes, has investigated the gut microbial composition in a cohort of 123 non-obese and 169 obese Danish individuals. This study showed for the first time that 2 groups of individuals can be distinguished in the population by the richness of gut microbiota. The latest results were published online in Nature today.

Obesity, known as "the modem civilized disease", is a leading preventable cause of death worldwide that increases the likelihood of various diseases, particularly heart disease, type 2 diabetes, and others. It's reported that the obesity epidemic will affect more than 700 million in 2015 and will continue to grow. Each of our guts is colonized by more than 3 pounds of microorganisms. More and more data show that our "other" genome, the microbiome, may have greater consequences on the onset of obesity.

In this study, researchers analyzed the gut bacterial composition of 292 Danish adults by a new analytical approach called quantitative metagenomics. They found two groups of individuals that differ by the number of gut microbial genes and thus gut bacterial richness. A quarter of the cohort is "poor" in bacteria (low bacterial richness), whereas the rest is "rich" (high bacterial richness); Low richness individuals included a significantly higher proportion of obese participants and were as a group characterized by a more marked adiposity.

Their further efforts showed that the low richness microbiota contains higher proportion of pro-inflammatory and lower proportion of anti-inflammatory bacterial species than the high richness one. The two groups of individuals could be almost perfect stratified with very few bacteria, suggesting that simple molecular diagnostic tests, based upon the gut microbiome, can be developed to identify individuals at risk of common morbidi
'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Page: 1 2

Related biology news :

1. Bacterial toxins cause deadly heart disease
2. UC Davis researchers discover molecular target for the bacterial infection brucellosis
3. High-angle helix helps bacteria swim
4. Newly discovered bacterial partnership changes ocean chemistry
5. Bacterial blockade
6. Study finds depletion of alveolar macrophages linked to bacterial super-infections
7. New methods to visualize bacterial cell-to-cell communication
8. Bacteria from Salar de Uyuni in Bolivia conceal bioplastic
9. CWRU dental researchers NIDCR grant targets oral bacteria and fetal death link
10. Genomes of cholera bacteria from Haiti confirm epidemic originated from single source
11. UT study: Chemical in antibacterial soaps may harm nursing babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... (Sept. 4, 2008) A variety of organismsfrom ... where the timing and duration of fundamental biological processes ... survive, even under fluctuating environmental conditions. In recent ... molecular basis of these rhythms and how they translate ...
... Breast Cancer Symposium features the latest cutting-edge findings in ... meeting focuses on new and promising therapeutic approaches, as ... breast cancer. To help you take the best ... we encourage you to visit www.sabcs.org to ...
... September 4, 2008) The tumor suppressor gene ... in cases of soft tissue sarcoma (STS), according ... at the Sbarro Institute for Cancer Research and ... Technology at Temple University in Philadelphia, PA, the ...
Cached Biology News:Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2International team reveals first prognosticator of survival in aggressive cancer 2
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... , August 3, 2015 According ... on 3D Cell Culture: Asia ... Market Research, the global 3D cell culture market was valued at ... expand at a CAGR of 29.1% to account for ... Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... a privately,held biotechnology company, announced that it has ... Series D preferred stock offering with its investor,syndicate ... Ventures,L.P., Boston Medical Investors and Silicon Valley Bank ... Chairman of the Board. The Company,expects a second ...
... Application in the ... European Union, ... Food and Drug Administration (FDA) has approved the design of,a single, ... with chemotherapy as first-line,treatment in patients with non-small cell lung cancer ...
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
Cached Biology Technology:Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5Pharmaxis' Aridol Gains First Asian Approval 2
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
LTBP-2 (7B10)...
... Product Rabbit polyclonal to Kv4.2 ... to KLH, corresponding to amino acids 23-43 ... Cross-reacts with Rat.Expected to cross-react with ... identity with immunogen), Rabbit (100% identity with ...
Mouse Anti-Gemin2...
Biology Products: